Clinical TrialMay 21, 2026, 05:03 PM
Syndax to Present Favorable Revuforj Data at ASCO 2026
AI Summary
Syndax Pharmaceuticals announced the acceptance of four Revuforj® (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. An oral presentation will highlight favorable outcomes observed among 21 adults and children with acute leukemia who received revumenib post-transplant, including overall survival and relapse rates. Additionally, data on revumenib's pharmacokinetic profile, demonstrating its compatibility with gastric acid reducing agents and low-fat meals, will be presented. The company will also showcase the design of ongoing pivotal Phase 3 trials for revumenib in newly diagnosed acute leukemia.
Key Highlights
- Syndax to present 4 Revuforj (revumenib) abstracts at ASCO Annual Meeting (May 29 – June 2, 2026).
- Oral presentation to highlight favorable outcomes for 21 acute leukemia patients receiving revumenib post-transplant.
- Data will include observed overall survival and relapse rates compared to a historical cohort.
- Poster presentation to detail revumenib's PK profile, including compatibility with gastric acid reducing agents and low-fat meals.
- Two 'Trial in progress' posters will outline Phase 3 studies for revumenib in newly diagnosed NPM1m or KMT2Ar acute leukemia.
- Revuforj is an FDA-approved menin inhibitor for relapsed or refractory acute leukemia.
Price Impact
More from SNDX